Quick Answer: Usually not. Malpractice responds to bodily injury from negligent care or advice. A practice that buys peptides wholesale and sells them to patients becomes a seller in the product liability claims pipeline, with the same product claims exposure as any distributor. That exposure requires products liability, and advice on non-FDA-approved peptides requires a separate peptide malpractice policy.
A practice that buys peptides wholesale and sells them to patients at retail takes on two distinct roles. As a clinician, it recommends the peptide and sets the protocol. As a seller, it becomes part of the product’s distribution chain, with the same product claims exposure as any distributor. A single adverse outcome can trigger claims against both roles at once.
Where Does the Risk Actually Sit?
Peptide operations create eight distinct exposures, each answered by different policy language. Review each one on its own terms, then coordinate them.
The most common mistake is assuming a malpractice policy covers all eight. It does not respond to product exposure, and no policy insures the indemnification promises in a supply agreement.
A Congressional Research Service survey of state products liability law notes that, in many states, “the manufacturer and any seller in the chain of distribution may be held strictly liable.”
Two Exposures, One Patient
Conventional malpractice carriers do not cover exposures arising from recommendations or advice involving non-FDA-approved peptides, and malpractice coverage generally does not respond to product exposure at all. A practice may discover that gap only after a claim is filed. Rather than altering the primary malpractice policy, which continues to protect the practice’s conventional operations, this program places the peptide exposure on a separate policy designed to transfer it.
Your purchase agreement with your distributor typically contains bilateral indemnification, with each party answering for what it controls. The distributor and manufacturer answer for the product as made. The practice answers for storage, handling, recommendations, and administration. The two policies in this program are built to insure the practice’s own liability for what it controls: products liability for storage and handling, and peptide malpractice for recommendations and administration.
- Product claims. Bodily injury alleged to arise from a peptide your practice sold or administered, including product compromised while in your storage.
- Professional claims. Injury alleged to result from a negligent recommendation, a dosing protocol, or a failure to screen for contraindications.
- Medical director exposure. The physician who oversees the program can be named personally for the protocols and oversight behind it.
- Malpractice gaps. Conventional malpractice policies do not cover exposures arising from non-FDA- approved peptides, and they do not respond to product exposure.
What Does This Program Include?
The program consists of two separate policies, each written for a distinct exposure. Peptide Products Liability, written on a general liability form, responds when the peptide itself is alleged to have caused harm. The peptide malpractice policy responds when a patient alleges bodily injury caused by negligent advice on peptide use. Because many peptide claims involve both, carrying both policies helps ensure that each exposure has a policy designed to respond to it.
The peptide malpractice policy requires that general liability coverage, including products and completed operations, be in place. Policy 1 satisfies that requirement, so the two policies are designed to be carried together.
What a Peptide Claim Looks Like for a Practice
To save patients a second visit, front-desk staff assemble take-home kits containing vials, diluent, and syringes. Two peptides with similar vial labels are stocked side by side, and a patient’s kit is packed with the wrong one. The patient follows the instructions, injects a peptide that was never recommended, and suffers a serious adverse reaction. The claim alleges the practice dispensed the wrong product and names the practice as the seller.
A physician recommends a growth hormone-releasing peptide protocol for recovery and body composition. The patient’s history of poorly controlled diabetes is noted at intake, but no baseline labs are drawn and blood glucose is never monitored. Several weeks into the protocol, the patient is hospitalized with severe hyperglycemia. The suit alleges negligent advice and a failure to screen and monitor. It names the practice and the physician, and the medical director who approved the protocol is named personally.
For a practice, these scenarios rarely stay separate. When a patient is injured by a peptide the practice both recommended and sold, the product claim will most likely be accompanied by a malpractice claim. That doubles the legal expense in the matter, and those costs sit outside whatever a settlement or the indemnification language in your purchase agreement may dictate. A malpractice policy that excludes peptides, or does not respond to product exposure, leaves the practice to fund both defenses itself.
Will Adding Peptide Malpractice Coverage Affect My Existing Policy?
This policy is written to ride alongside your primary malpractice policy, not replace it. The primary policy is left untouched so that it continues to protect the conventional operational exposures it was designed for. Because conventional malpractice carriers do not cover non-FDA-approved peptide exposures, a separate policy is used to transfer that particular exposure to a carrier that will insure it.
Who Is Eligible?
- Physician practices and clinics with a licensed physician overseeing peptide use
- Products labeled “For Professional Use Only”
- Product sourced from a reputable manufacturer or distributor, not the open market
- Product provided to patients through the medical channel under the practice’s or practitioner’s NPI number
Not Eligible: Research Use Only (RUO) peptides used clinically or sold outside the physician channel, and any direct-to-consumer sales.
Med spas adding peptide services are insured under our Med Spa program. Ask a broker which program fits your practice.
Frequently Asked Questions
1. Will adding peptide malpractice coverage affect my existing policy?
No. Peptide malpractice is written to ride alongside your primary malpractice policy and leaves it untouched, so it continues to protect your conventional operations.
2. Are certain peptides excluded from coverage?
No. The program imposes no exclusions based on peptide type. Eligibility depends on “For Professional Use Only” labeling, reputable sourcing, and products provided through the medical channel under a licensed provider’s NPI number.
3. Can direct-to-consumer peptide sales be insured?
Not under this program. Carriers require professional-use labeling and a licensed provider in the chain, so direct-to-consumer sales fall outside the program.
4. Does World Insurance Network only write peptide coverage?
No. World Insurance Network is a full-service brokerage. Peptide coverage is one specialty alongside a complete range of commercial and personal insurance coverages sold.
5. When should I expect a response?
A licensed broker responds to you directly, not a call center. Submit a Coverage Gap Review request or call us, and we will reply during normal business hours.
Tell us what you need covered. A broker will review your request and respond during normal business hours. Call 725-269-2721 or Talk to a Broker.
Key Takeaways
- Peptide exposure has more than one component. Products liability, professional liability, product recall, and peptide malpractice each insure a distinct exposure and warrant independent evaluation.
- Buying products for resale creates product exposure. A practice or med spa that resells product to patients assumes the liability of a distributor, an exposure only products liability insurance is designed to address.
- Malpractice generally addresses professional care or advice resulting in bodily injury, not product exposure. Product claims require separate products coverage.
- Unlike many policies, our program imposes no exclusions based on peptide type. Eligibility depends instead on professional-use labeling, physician oversight, and reputable sourcing.
- The program complements existing malpractice coverage. Peptide malpractice rides alongside your primary policy and leaves it untouched.
- Purchase agreements carry bilateral indemnification. Each party answers for what it controls, and its insurance coverage should match its contractual obligations.